Immune privilege for stem cells: not as simple as it looked.

Area of Science:

• Stem cell biology
• Immunology
• Regenerative medicine

Background:

• Human embryonic stem cells (hESCs) were previously thought to be immune privileged.
• This immune privilege could have facilitated their use in transplantation therapies.
• Recent findings challenge this long-held assumption.

Discussion:

• The study demonstrates that hESCs elicit an immune response.
• This immune response involves T-cell mediated rejection.
• The cells are not inherently protected from the host immune system.

Key Insights:

• Human embryonic stem cells are immunogenic and can be rejected by the host immune system.
• The concept of immune privilege for hESCs is not valid.
• This finding has significant implications for hESC-based therapies.

Outlook:

• Development of novel immunosuppression or immune-evasive strategies is crucial.
• Strategies to overcome immune rejection are necessary for clinical translation of hESC therapies.
• Further research into immune interactions with hESCs is warranted.